세계의 장골 스텐트 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 동맥 병변별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Iliac Stent Market Size, Share & Trends Analysis Report By Type (Self-expandable Stents, Balloon-expandable Stents), By Artery Lesions (Common Iliac Artery Lesions, Severe Calcified Lesion), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,191,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,568,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,321,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

장골 스텐트 시장의 성장과 동향 :

Grand View Research, Inc의 최신 보고서에 따르면 세계 장골 스텐트 시장 규모는 2030년까지 15억 3,000만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 5.8% 성장할 전망입니다.

말초동맥질환의 유병률 증가, 의료기술의 발전, 심혈관질환의 효과적인 치료 옵션으로서 최소침습적 시술에 대한 인식 확대 등의 요인으로 인해 이 시장은 성장할 것으로 예상됩니다.

이 산업의 성장을 주도하는 것은 신제품 개발과 개통성을 높인 정렬술입니다. 예를 들어, 자가 확장형 스텐트는 외장골 동맥 치료에서 우수한 결과를 보이고 있습니다. 또한, 2023년 10월 Institute for Health Metrics and Evaluation의 발표에 따르면, PAD의 전 세계 유병률은 1.52%, 약 1억 1,300만 명에 달할 것으로 예상됩니다. 인 것으로 추정하고 있습니다. 또한, 2022년 NCBI의 논문에서는 PAD의 연간 발병률이 1,000만 명에 육박할 것으로 예측했습니다.

장골 스텐트 시장의 주요 업체들의 전략적 이니셔티브가 증가하면서 성장을 가속할 것으로 예상됩니다. 예를 들어, 2024년 1월 Zylox-Tonbridge Medical Technology Co.Ltd.는 NMPA(National Medical Products Administration)로부터 말초 정맥 스텐트 시스템의 판매 승인을 획득했습니다. 또한 2023년 10월, Getinge AB는 미국에서 장골동맥 폐쇄성 질환 치료용 iCast 커버 스텐트 시스템을 시판한다고 발표했습니다.

장골 스텐트 시장 보고서 하이라이트

• 헬스케어 산업의 장골 스텐트 시장은 2023년 10억 3,000만 달러로 추정되며, 2030년에는 15억 3,000만 달러에 달할 것으로 예상됩니다.
• 장골 스텐트 시장은 2024년부터 2030년까지 연평균 5.8%의 복합 성장률로 성장하여 2030년에는 1.53억 달러에 달할 것으로 예상됩니다.
• 2023년 북미는 장골 스텐트 시장에서 가장 큰 점유율을 차지하며 43.7%의 매출 점유율을 기록할 것으로 예상됩니다. 미국에서는 PAD에 취약한 노인 인구가 증가함에 따라 스텐트 삽입술에 대한 수요가 증가하여 예측 기간 동안 시장 성장에 큰 기여를 할 것으로 예상됩니다.
• 스텐트 유형별로는 자가 확장형 스텐트가 2023년 60.4%로 가장 큰 매출 점유율을 차지할 것으로 예상되는데, 이는 이러한 스텐트에 대한 양호한 장기 임상시험 결과가 의료 서비스 제공업체에게 신뢰를 줄 것으로 예상되기 때문입니다.
• 동맥 병변별로는 총 장골 동맥 병변 부문이 2023년 60.5%의 가장 큰 매출 점유율을 차지할 것으로 예상됩니다. 고콜레스테롤 및 비만 환자가 증가함에 따라 장골 스텐트에 대한 수요가 증가할 것으로 예상됩니다.
• 최종 용도별로는 병원 부문이 2023년 61.7%로 압도적인 매출 점유율을 차지할 것으로 예상됩니다. 병원은 환자가 영상 진단, 의료 관리, 장골 스텐트 삽입과 같은 중재적 시술을 포함한 종합적인 치료를 받을 수 있는 의뢰 센터 역할을 합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 장골 스텐트 시장 : 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 장골 스텐트 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 장골 스텐트 시장 : 유형 추정·동향 분석

• 장골 스텐트 시장 : 유형 대시보드
• 장골 스텐트 시장 : 유형 변동 분석
• 장골 스텐트 시장 규모, 유형별, 예측 및 동향 분석, 2018-2030년
• 자기 확장형 스텐트
• 풍선 확장형 스텐트
• 기타

제5장 장골 스텐트 시장 : 동맥 병변 추정·동향 분석

• 장골 스텐트 시장 : 동맥 병변 대시보드
• 장골 스텐트 시장 : 동맥 병변 변동 분석
• 장골 스텐트 시장 규모, 동맥 병변별, 예측 및 동향 분석, 2018-2030년
• 일반 장골 동맥 병변
• 석회화 병변
• 완전 폐쇄성 병변

제6장 장골 스텐트 시장 : 최종 용도 추정·동향 분석

• 장골 스텐트 시장 : 최종 용도 대시보드
• 장골 스텐트 시장 : 최종 용도 변동 분석
• 장골 스텐트 시장 규모, 최종 용도별, 예측 및 동향 분석, 2018-2030년
• 병원
• 외래시설
• 기타

제7장 장골 스텐트 시장 : 지역 추정·동향 분석, 국가별, 유형별, 동맥 병변별, 최종 용도별

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 예측 기간 동안 연평균 복합 성장률(CAGR)
• 벤더 구도
  • BD
  • Abbott
  • Boston Scientific Corporation
  • WL Gore & Associates, Inc.
  • Cook
  • Medtronic
  • Vascular
  • Terumo Corporation
  • Getinge AB
  • Biotronik SE &Co KG

LSH

영문 목차

영문목차

Iliac Stent Market Growth & Trends:

The globall iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030, based on a new report by Grand View Research, Inc. The market is expected to grow due to factors such as the increasing prevalence of peripheral artery diseases, growing advancements in medical technology, and expanding awareness about minimally invasive procedures as an effective treatment option for cardiovascular diseases.

The industry's growth is driven by new product development and aligned procedures with enhanced patency. For instance, self-expanding stents have demonstrated exceptional results in the treatment of external iliac artery. Furthermore, the growing prevalence of peripheral artery disease (PAD) is expected to propel iliac stents market growth. According to an article by the Institute for Health Metrics and Evaluation in October 2023, the global prevalence of PAD was pegged at 1.52% or nearly 113 million people. Additionally, NCBI's article in 2022 projected the annual incidence of PAD to be nearly 10 million.

An increase in strategic initiatives amongst the key players of iliac stents is anticipated to propel growth. For instance, in January 2024, Zylox-Tonbridge Medical Technology Co., Ltd. received marketing approval from the National Medical Products Administration (NMPA) for its peripheral venous stent system. Furthermore, in October 2023, Getinge AB announced the commercial availability of its product, iCast covered stent system to treat iliac arterial occlusive disease in the U.S.

Iliac Stents Market Report Highlights:

• The iliac stents marketin the healthcare industry was estimated at USD 1.03 Billion in 2023 and is expected to reach USD 1.53 Billion in 2030
• The iliac stents marketis expected to grow at a compound annual growth rate of 5.8% from 2024 to 2030 to reach USD 1.53 Billion by 2030
• In 2023, North America held the largest share in the iliac stents market, with a revenue share of 43.7%. The growing geriatric population in the U.S., which is susceptible to PAD is expected to increase the demand for stenting procedures, thereby significantly contributing to the market growth over the forecast period
• By type, self-expandable stents segment accounted for the largest revenue share of 60.4% in 2023driven by favorable long-term clinical study results for these stents that are expected to instill confidence in healthcare providers
• By artery lesions, the common iliac artery lesions segment accounted for the largest revenue share of 60.5% in 2023 driven by growing cases of patients suffering from high cholesterol and obesity are expected to boost the demand for iliac stents, as these conditions cause plaque buildup, which narrows or blocks artery lumen
• By end use, hospital segment accounted for a dominant revenue share of 61.7% in 2023. Hospitals serve as referral centers where patients receive comprehensive care, including diagnostic imaging, medical management, and interventional procedures like iliac stent placement

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Artery lesions
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for Primary Interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Parent market analysis (Model 2)
  • 1.7.4. Approach 2: Parent market analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment outlook
  • 2.2.1. Type outlook
  • 2.2.2. Artery lesions outlook
  • 2.2.3. End-use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Iliac Stents Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of peripheral artery disease (PAD)
    • 3.2.1.2. Technological advancements in iliac stents
    • 3.2.1.3. Increasing number of product approvals in developed and developing countries
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of reimbursement policies for venous stenting
    • 3.2.2.2. Product recalls
• 3.3. Iliac Stents Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Iliac Stents Market: Type Estimates & Trend Analysis

• 4.1. Iliac Stent Market: Type Dashboard
• 4.2. Iliac Stent Market: Type Movement Analysis
• 4.3. Iliac Stents Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Self-Expandable Stents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Balloon-Expandable Stents
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Iliac Stents Market: Artery Lesions Estimates & Trend Analysis

• 5.1. Iliac Stent Market: Artery Lesions Dashboard
• 5.2. Iliac Stent Market: Artery Lesions Movement Analysis
• 5.3. Iliac Stents Market Size & Forecasts and Trend Analysis, by Artery Lesion, 2018 to 2030 (USD Million)
• 5.4. Common Iliac Artery Lesions
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Severe Calcified Lesions
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Complete Obstructive Lesions
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Iliac Stents Market: End-Use Estimates & Trend Analysis

• 6.1. Iliac Stent Market: End-Use Dashboard
• 6.2. Iliac Stent Market: End-Use Movement Analysis
• 6.3. Iliac Stents Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Outpatient Facilities
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Iliac Stents Market: Regional Estimates & Trend Analysis by Country, Type, Artery Lesions, & End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/ reimbursement structure
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Mexico
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Argentina
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa Market Estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. BD
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Abbott
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Boston Scientific Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. W. L. Gore & Associates, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Cook
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Medtronic
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Vascular
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Terumo Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Getinge AB
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Biotronik SE & Co KG
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives

관련자료